{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T23:07:25Z","timestamp":1774307245357,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,8,24]],"date-time":"2018-08-24T00:00:00Z","timestamp":1535068800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,8,24]],"date-time":"2018-08-24T00:00:00Z","timestamp":1535068800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Current Chinese national guidelines recommend routine screening for liver cancer in patients positive for HBsAg, irrespective of fibrosis status, age, or family history of liver cancer. We aim to evaluate whether the recommended screening strategy could reduce liver-cancer-specific mortality. We conducted a liver cancer mass screening trial in Xiaolan Town, Zhongshan City, China, among residents aged 35\u201364 years in 2012. All volunteers were offered serological testing for hepatitis B virus surface antigen (HBsAg). We proposed biannual screening using serum alpha-fetoprotein (AFP) and ultrasonography examination for subjects positive for HBsAg. Among 17,966 participants (26.2% of 68,510 eligible residents) who were free of liver cancer at baseline in 2012, we identified 57 incident cases of liver cancer within the first 4 years of follow-up (i.e., 43 among 2,848 HBsAg-positive participants and 14 among 15,118 HBsAg-negative participants), compared with 104 cases identified in non-participants (N\u2009=\u200950,544). A total of 207 participants had the recommended number of ultrasonography examinations (every 6 months) during the screening period. Compared with cases identified from non-participants, the cases arising among participants were more likely to be at early stage and had better survival than those among non-participants. However, we did not observe a reduction in liver cancer-specific mortality rate among participants (relative risk\u2009=\u20091.04, 95% confidence interval\u2009=\u20090.68, 1.58, <jats:italic>P<\/jats:italic>\u2009=\u20090.856). Our demonstration screening study does not show a reduction in liver cancer mortality within the first 4 years of follow-up according to current guidance in China, although long-term efficacy remains to be evaluated. Targeted surveillance among high-risk individuals as recommended by international guidelines, along with measures to improve compliance, should be evaluated in the Chinese population.<\/jats:p>","DOI":"10.1038\/s41598-018-31119-9","type":"journal-article","created":{"date-parts":[[2018,8,20]],"date-time":"2018-08-20T14:09:20Z","timestamp":1534774160000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Mass screening for liver cancer: results from a demonstration screening project in Zhongshan City, China"],"prefix":"10.1038","volume":"8","author":[{"given":"Mingfang","family":"Ji","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0136-651X","authenticated-orcid":false,"given":"Zhiwei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen T.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biaohua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qianjin","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuangrong","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuejun","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shifeng","family":"Lian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen","family":"Quan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panpan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiheng","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shenglin","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fugui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weimin","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiqiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weimin","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,8,24]]},"reference":[{"key":"31119_CR1","unstructured":"Ferlay, J. et al. GLOBOCAN 2012v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http:\/\/globocan.iarc.fr, accessed on 04\/02\/2016."},{"key":"31119_CR2","unstructured":"Forman D et al. Cancer Incidence in Five Continents, Vol. X (electronic version) Lyon, IARC (2013)."},{"key":"31119_CR3","doi-asserted-by":"publisher","unstructured":"Chen, W. et al. Cancer statistics in China, 2015. CA: a cancer journal for clinicians, https:\/\/doi.org\/10.3322\/caac.21338 (2016).","DOI":"10.3322\/caac.21338"},{"key":"31119_CR4","doi-asserted-by":"publisher","first-page":"7251","DOI":"10.7314\/APJCP.2013.14.12.7251","volume":"14","author":"JH Fan","year":"2013","unstructured":"Fan, J. H. et al. Attributable causes of liver cancer mortality and incidence in china. Asian Pac J Cancer Prev 14, 7251\u20137256 (2013).","journal-title":"Asian Pac J Cancer Prev"},{"key":"31119_CR5","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1002\/hep.27969","volume":"62","author":"C de Martel","year":"2015","unstructured":"de Martel, C., Maucort-Boulch, D., Plummer, M. & Franceschi, S. World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma. Hepatology 62, 1190\u20131200, https:\/\/doi.org\/10.1002\/hep.27969 (2015).","journal-title":"Hepatology"},{"key":"31119_CR6","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.4161\/21645515.2014.980206","volume":"11","author":"X Liao","year":"2015","unstructured":"Liao, X. & Liang, Z. Strategy vaccination against Hepatitis B in China. Hum Vaccin Immunother 11, 1534\u20131539, https:\/\/doi.org\/10.4161\/21645515.2014.980206 (2015).","journal-title":"Hum Vaccin Immunother"},{"key":"31119_CR7","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/hep.510290145","volume":"29","author":"JM Llovet","year":"1999","unstructured":"Llovet, J. M. et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 29, 62\u201367, https:\/\/doi.org\/10.1002\/hep.510290145 (1999).","journal-title":"Hepatology"},{"key":"31119_CR8","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1097\/MOG.0b013e32835ff1cf","volume":"29","author":"KT Padhya","year":"2013","unstructured":"Padhya, K. T., Marrero, J. A. & Singal, A. G. Recent advances in the treatment of hepatocellular carcinoma. Curr Opin Gastroenterol 29, 285\u2013292, https:\/\/doi.org\/10.1097\/MOG.0b013e32835ff1cf (2013).","journal-title":"Curr Opin Gastroenterol"},{"key":"31119_CR9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1177\/1756283X10385964","volume":"4","author":"HB El-Serag","year":"2011","unstructured":"El-Serag, H. B. & Davila, J. A. Surveillance for hepatocellular carcinoma: in whom and how? Therap Adv Gastroenterol 4, 5\u201310, https:\/\/doi.org\/10.1177\/1756283X10385964 (2011).","journal-title":"Therap Adv Gastroenterol"},{"key":"31119_CR10","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/hep.29086","volume":"67","author":"JK Heimbach","year":"2018","unstructured":"Heimbach, J. K. et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 67, 358\u2013380, https:\/\/doi.org\/10.1002\/hep.29086 (2018).","journal-title":"Hepatology"},{"key":"31119_CR11","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s12072-017-9799-9","volume":"11","author":"M Omata","year":"2017","unstructured":"Omata, M. et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int 11, 317\u2013370, https:\/\/doi.org\/10.1007\/s12072-017-9799-9 (2017).","journal-title":"Hepatol Int"},{"key":"31119_CR12","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1258\/096914103771773320","volume":"10","author":"JG Chen","year":"2003","unstructured":"Chen, J. G. et al. Screening for liver cancer: results of a randomised controlled trial in Qidong, China. Journal of medical screening 10, 204\u2013209, https:\/\/doi.org\/10.1258\/096914103771773320 (2003).","journal-title":"Journal of medical screening"},{"key":"31119_CR13","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s00432-004-0552-0","volume":"130","author":"BH Zhang","year":"2004","unstructured":"Zhang, B. H., Yang, B. H. & Tang, Z. Y. Randomized controlled trial of screening for hepatocellular carcinoma. Journal of cancer research and clinical oncology 130, 417\u2013422, https:\/\/doi.org\/10.1007\/s00432-004-0552-0 (2004).","journal-title":"Journal of cancer research and clinical oncology"},{"key":"31119_CR14","doi-asserted-by":"publisher","first-page":"261","DOI":"10.7326\/M14-0558","volume":"161","author":"D Kansagara","year":"2014","unstructured":"Kansagara, D. et al. Screening for hepatocellular carcinoma in chronic liver disease: a systematic review. Ann Intern Med 161, 261\u2013269, https:\/\/doi.org\/10.7326\/M14-0558 (2014).","journal-title":"Ann Intern Med"},{"key":"31119_CR15","doi-asserted-by":"publisher","unstructured":"Aghoram, R., Cai, P. & Dickinson, J. A. Alpha-foetoprotein and\/or liver ultrasonography for screening of hepatocellular carcinoma in patients with chronic hepatitis B. Cochrane Database Syst Rev, CD002799, https:\/\/doi.org\/10.1002\/14651858.CD002799.pub2 (2012).","DOI":"10.1002\/14651858.CD002799.pub2"},{"key":"31119_CR16","first-page":"631","volume":"24","author":"L Zhi-heng","year":"2015","unstructured":"Zhi-heng, L., Xia-biao, P., Hui-shan, C. & Wei, K. An Analysis of Incidence of Liver Cancer in Zhongshan,1970~2010 (in Chinese). China Cancer 24, 631\u2013637 (2015).","journal-title":"China Cancer"},{"key":"31119_CR17","first-page":"638","volume":"24","author":"L Zhi-heng","year":"2015","unstructured":"Zhi-heng, L., Xia-biao, P., Hui-shan, C. & Wei, K. An Analysis of Mortality of Liver Cancer in Zhongshan, 1970~2010 (in Chinese). China Cancer 24, 638\u2013644 (2015).","journal-title":"China Cancer"},{"key":"31119_CR18","doi-asserted-by":"publisher","first-page":"10573","DOI":"10.3748\/wjg.v21.i37.10573","volume":"21","author":"N Tsuchiya","year":"2015","unstructured":"Tsuchiya, N. et al. Biomarkers for the early diagnosis of hepatocellular carcinoma. World journal of gastroenterology 21, 10573\u201310583, https:\/\/doi.org\/10.3748\/wjg.v21.i37.10573 (2015).","journal-title":"World journal of gastroenterology"},{"key":"31119_CR19","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1111\/j.1572-0241.2006.00467.x","volume":"101","author":"A Colli","year":"2006","unstructured":"Colli, A. et al. Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am J Gastroenterol 101, 513\u2013523, https:\/\/doi.org\/10.1111\/j.1572-0241.2006.00467.x (2006).","journal-title":"Am J Gastroenterol"},{"key":"31119_CR20","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1093\/jnci\/djs372","volume":"104","author":"CP Wen","year":"2012","unstructured":"Wen, C. P. et al. Hepatocellular carcinoma risk prediction model for the general population: the predictive power of transaminases. J Natl Cancer Inst 104, 1599\u20131611, https:\/\/doi.org\/10.1093\/jnci\/djs372 (2012).","journal-title":"J Natl Cancer Inst"},{"key":"31119_CR21","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1002\/hep.26703","volume":"59","author":"YP Yeh","year":"2014","unstructured":"Yeh, Y. P. et al. Evaluation of abdominal ultrasonography mass screening for hepatocellular carcinoma in Taiwan. Hepatology 59, 1840\u20131849, https:\/\/doi.org\/10.1002\/hep.26703 (2014).","journal-title":"Hepatology"},{"key":"31119_CR22","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1200\/JCO.2009.27.4456","volume":"28","author":"HI Yang","year":"2010","unstructured":"Yang, H. I. et al. Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Clin Oncol 28, 2437\u20132444, https:\/\/doi.org\/10.1200\/JCO.2009.27.4456 (2010).","journal-title":"J Clin Oncol"},{"key":"31119_CR23","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/S1470-2045(11)70077-8","volume":"12","author":"HI Yang","year":"2011","unstructured":"Yang, H. I. et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol 12, 568\u2013574, https:\/\/doi.org\/10.1016\/S1470-2045(11)70077-8 (2011).","journal-title":"Lancet Oncol"},{"key":"31119_CR24","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/hep.24199","volume":"53","author":"J Bruix","year":"2011","unstructured":"Bruix, J. & Sherman, M., American Association for the Study of Liver, D.. Management of hepatocellular carcinoma: an update. Hepatology 53, 1020\u20131022, https:\/\/doi.org\/10.1002\/hep.24199 (2011).","journal-title":"Hepatology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-31119-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-31119-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-31119-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T09:02:02Z","timestamp":1671613322000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-31119-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,24]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["31119"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-31119-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,24]]},"assertion":[{"value":"15 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"12787"}}